Glycostem

Executive Summary

Glycostem is a private Dutch biotechnology company focused on developing stem cell-derived natural killer (NK) cell therapies for oncology. Founded in 2012 and headquartered in Oss, Netherlands, the company leverages its proprietary platform to generate off-the-shelf NK cell products targeting hematologic malignancies, including acute myeloid leukemia (AML) and multiple myeloma (MM). Glycostem's approach aims to harness the innate tumor-killing capabilities of NK cells while improving scalability and consistency through stem cell derivation, addressing key limitations of patient-specific cell therapies. The company is currently in Phase 1/2 clinical development, with its lead candidate being evaluated for safety and efficacy in hard-to-treat blood cancers. As a private entity, Glycostem has not disclosed financial details, but its pipeline represents a promising avenue in the rapidly evolving cell therapy landscape. With increasing interest in allogeneic NK cell therapies, Glycostem's differentiated platform positions it for potential partnerships or further clinical validation.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 interim data readout for lead NK cell therapy in AML/MM50% success
• H2 2026Potential strategic partnership or licensing deal for manufacturing or regional rights40% success
• 2027Regulatory clearance for expansion to solid tumor indications30% success